ChemoCentryx Inc (CCXI) Expected to Announce Quarterly Sales of $9.56 Million
Equities analysts expect ChemoCentryx Inc (NASDAQ:CCXI) to post $9.56 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for ChemoCentryx’s earnings. The lowest sales estimate is $8.98 million and the highest is $10.00 million. ChemoCentryx reported sales of $56.30 million in the same quarter last year, which indicates a negative year-over-year growth rate of 83%. The company is expected to announce its next quarterly earnings report on Friday, March 8th.
On average, analysts expect that ChemoCentryx will report full-year sales of $42.95 million for the current financial year, with estimates ranging from $42.50 million to $43.54 million. For the next year, analysts forecast that the company will post sales of $35.28 million, with estimates ranging from $100,000.00 to $60.00 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for ChemoCentryx.
ChemoCentryx (NASDAQ:CCXI) last announced its quarterly earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.03. ChemoCentryx had a net margin of 13.88% and a return on equity of 32.16%. The firm had revenue of $8.98 million for the quarter, compared to analyst estimates of $11.55 million.
In other ChemoCentryx news, insider Markus J. Cappel sold 30,237 shares of the stock in a transaction dated Friday, October 26th. The shares were sold at an average price of $11.01, for a total transaction of $332,909.37. Following the sale, the insider now owns 54,063 shares of the company’s stock, valued at approximately $595,233.63. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Thomas J. Schall sold 7,211 shares of the stock in a transaction dated Wednesday, November 7th. The stock was sold at an average price of $12.00, for a total transaction of $86,532.00. Following the sale, the insider now directly owns 2,192,205 shares in the company, valued at approximately $26,306,460. The disclosure for this sale can be found here. In the last ninety days, insiders sold 7,380,940 shares of company stock worth $86,264,863. 14.50% of the stock is owned by insiders.
Large investors have recently modified their holdings of the business. Sei Investments Co. grew its holdings in ChemoCentryx by 203.5% during the 2nd quarter. Sei Investments Co. now owns 8,549 shares of the biopharmaceutical company’s stock worth $113,000 after acquiring an additional 5,732 shares during the last quarter. Macquarie Group Ltd. bought a new stake in ChemoCentryx during the 2nd quarter worth about $130,000. grace capital bought a new stake in ChemoCentryx during the 2nd quarter worth about $132,000. Paloma Partners Management Co bought a new stake in ChemoCentryx during the 2nd quarter worth about $159,000. Finally, Trexquant Investment LP grew its holdings in ChemoCentryx by 47.4% during the 2nd quarter. Trexquant Investment LP now owns 17,056 shares of the biopharmaceutical company’s stock worth $225,000 after acquiring an additional 5,482 shares during the last quarter. 54.59% of the stock is currently owned by hedge funds and other institutional investors.
Shares of CCXI traded up $0.23 during trading hours on Friday, hitting $9.76. The stock had a trading volume of 9,918 shares, compared to its average volume of 163,736. The company has a debt-to-equity ratio of 0.69, a quick ratio of 2.87 and a current ratio of 2.87. ChemoCentryx has a 52 week low of $5.42 and a 52 week high of $15.08. The firm has a market cap of $477.47 million, a price-to-earnings ratio of 26.64 and a beta of 1.78.
ChemoCentryx Company Profile
ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.